MK-2206

MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O. It acts as an allosteric AKT inhibitor.
It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.
It is intended to be used with other cancer therapies that advanced tumours may become resistant to.
Clinical trials.
2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated.
<br>2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.
<br>2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials.
<br> 31 phase II clinical trials are registered, many completed. e.g. in colorectal cancer, breast cancer, and many others.